Photon-counting CT in Chest Imaging

Last updated: January 26, 2026
Sponsor: Duke University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Copd (Chronic Obstructive Pulmonary Disease)

Treatment

Energy-integrating CT

Photon-counting CT

Clinical Study ID

NCT07031336
PRO00117084
  • All Genders

Study Summary

Purpose and objective: This project aims to evaluate photon-counting computed tomography (PCCT) quantitative accuracy using COPDGene subjects. The goal is to establish acquisition protocols for PCCT scans with proper post-processing (e.g., reconstruction parameters and harmonization techniques) that enable reproducible measurements of emphysema metrics (e.g., Perc15, LAA-950, HU accuracy) and airways (Pi10, WA%) in the lungs.

Study activities and population group: The study will recruit subjects from a current study at Duke (COPDGene Phase 4, Pro00113442). Here are the aims:

  • The research team will request consent from participants to acquire PCCT scans at their Phase 4 COPDGene visit. Scans will be performed using a PCCT-specific protocol.

  • Reconstruct the PCCT images with multiple post-acquisition parameter settings. Apply harmonization techniques that are recently developed by the investigators of this study.

Data analysis:

  • Identify the reconstruction and harmonization conditions that enable reproducible measurements of emphysema metrics (perc15, LAA-950, HU accuracy) and airways (Pi10, WA%), when compared to the counterpart EICT scans.

  • Demonstrate the non-inferiority and potentially improved capabilities of PCCT scans in cross-sectional and longitudinal studies.

Risk/safety issues:

The participants are asked to get an additional CT scan with a PCCT scanner at their COPDGene Phase 4 visit. This additional CT scan will be done using an inspiratory chest protocol with a total of 3 mGy (~1.5 mSv) radiation dose. This is roughly equivalent of 6 month of background radiation. Women who are pregnant will not have a chest CT scan done until they are confirmed to be not pregnant.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • This study recruit from the Duke-COPDGene Phase 4 study. All participants from thiscohort is eligible and they will be included if they consent.

Exclusion

Exclusion Criteria:

  • This study recruit from the Duke-COPDGene Phase 4 study. All participants from thiscohort is eligible and they will be included if they consent.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Energy-integrating CT
Phase:
Study Start date:
November 14, 2025
Estimated Completion Date:
May 12, 2026

Connect with a study center

  • Duke University Hospital

    Durham, North Carolina 27705
    United States

    Site Not Available

  • Duke University Hospital

    Durham 4464368, North Carolina 4482348 27705
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.